Zepbound Cost Without Insurance 2026

See if you qualify for Nouri →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: full refund if you're not satisfied in your first 30 days (3-month and 6-month plans) · cancel anytime

At a glance: Zepbound cost without insurance (2026)

Option	Estimated monthly cost (2026)	Notes
Zepbound vials — LillyDirect self-pay	$299–$449	2.5 mg $299 · 5 mg $399 · 7.5–15 mg $449 (Self-Pay Journey Program required)
Zepbound — retail list price	~$1,086	Sticker price; few self-pay patients pay this
Zepbound — with commercial insurance + savings card	As low as $25	Only if plan covers Zepbound; commercial coverage only (not Medicare/Medicaid)
Zepbound — Medicare (Bridge program)	~$50 (from July 1, 2026)	Verify eligibility and drug list at CMS.gov before relying on this figure
Wegovy (semaglutide) — self-pay	~$349	NovoCare self-pay program, as of June 2026; different drug, different molecule
Compounded tirzepatide — telehealth market range	~$125–$399	Not FDA-approved; not therapeutically equivalent to Zepbound
Compounded tirzepatide — Nouri (6-month plan)	$175/mo ($1,050 billed every 6 months)	All-in: medication when prescribed + nutrition + movement plan; not FDA-approved

Prices reflect publicly available information as of June 2026 and change frequently — verify current figures with the manufacturer, your pharmacy, and your insurer before making any decision. Sources: LillyDirect, NovoCare, and the Nouri GLP-1 telehealth pricing dataset (2026).

What does Zepbound cost without insurance in 2026?

Zepbound's retail list price is approximately $1,086 per month — the price at a standard pharmacy without any discount or insurance. Very few self-pay patients actually pay that amount. Eli Lilly created the LillyDirect Self-Pay Journey Program specifically so patients without insurance coverage can access Zepbound vials at a much lower price. Those self-pay vials are the realistic cash-pay option for most uninsured patients in 2026.

The key distinction is form factor: the self-pay vials are single-dose vials sold through LillyDirect's online pharmacy, not the autoinjector pens typically dispensed at retail pharmacies. The clinical dosing is the same; the delivery system differs. Patients draw from the vial and self-inject, following their prescriber's instructions.

How LillyDirect Self-Pay vials work

Through LillyDirect, Lilly sells Zepbound in three price tiers based on dose:

• 2.5 mg: approximately $299/month
• 5 mg: approximately $399/month
• 7.5 mg, 10 mg, 12.5 mg, and 15 mg: approximately $449/month

The $449 ceiling for all higher doses — regardless of which dose level in that range — is a notable feature of the program. However, staying at the $449 rate requires active participation in the Self-Pay Journey Program, which generally means refilling within approximately 45 days. If you let the program lapse and re-enroll, you may face a different price or conditions. Verify the current terms directly with LillyDirect before enrolling.

These prices do not include any clinical or telehealth service fee. A prescribing provider must write a prescription; LillyDirect does not prescribe. Some telehealth platforms include the consultation fee in their quoted price; others charge separately.

Zepbound with insurance: the $25 savings card

If your commercial health insurance plan covers Zepbound, Lilly offers a savings card that can reduce your out-of-pocket copay to as little as $25/month. Important caveats:

• This applies to commercial insurance only — it is not available to Medicare or Medicaid patients.
• Coverage is plan-specific. Many commercial plans exclude weight-loss drugs entirely. Prior authorization is commonly required.
• Some pharmacy benefit managers have shifted Zepbound's formulary status in 2025–2026 — confirming your current formulary before starting is essential.

If your plan denies coverage, ask your prescriber about a prior authorization (PA) or a medical exception request. Prior authorization success rates vary; your prescriber's office can advise whether it is worth pursuing. For more detail, see Does Insurance Cover Wegovy & Zepbound? and How to Get a GLP-1 Covered by Insurance.

Does Medicare cover Zepbound?

Medicare coverage for Zepbound has historically been restricted. A CMS Medicare GLP-1 Bridge program was announced with a target launch of July 1, 2026, with access pricing around $50/month for Medicare beneficiaries. Verify the current status, eligibility requirements, and covered drug list directly on the CMS press releases page before counting on this program — details and start dates are subject to change.

Medicaid coverage varies by state. As of 2026, a minority of state Medicaid programs cover GLP-1s for weight management — typically tied to obesity-as-disease policies. Check your state's Medicaid formulary directly.

Zepbound vs Wegovy cost comparison

At self-pay rates, Zepbound and Wegovy are priced closer than most people expect:

• Zepbound vials (LillyDirect): ~$299–$449/month (as of June 2026)
• Wegovy (NovoCare self-pay): ~$349/month (as of June 2026, per NovoCare; verify before deciding)

These are different drugs with different active molecules. Zepbound contains tirzepatide; Wegovy contains semaglutide. The published clinical trials study these as separate branded medications. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported a mean 20.9% body weight reduction with tirzepatide over 72 weeks in adults with obesity. The STEP 1 trial (Wilding et al., NEJM 2021) reported a mean 14.9% body weight reduction with semaglutide. These are results from trials of those specific branded molecules — individual results vary, and these findings do not represent expected outcomes for any compounded product.

For a full side-by-side breakdown, see Tirzepatide vs Semaglutide and Compounded Tirzepatide vs Zepbound. For the full cost landscape across all GLP-1 options, see the GLP-1 cost guide (2026 pillar).

Is there a cheaper or generic version of Zepbound?

There is no FDA-approved generic Zepbound. Tirzepatide's patent protection means a generic is not expected in the near term.

The two main lower-cost routes are:

1. LillyDirect Self-Pay vials (~$299–$449/month) — the lowest-price route for FDA-approved Zepbound.
2. Compounded tirzepatide (~$125–$399/month via telehealth) — prepared by state-licensed 503A compounding pharmacies and prescribed by licensed physicians. Compounded tirzepatide is not FDA-approved, not the same as Zepbound, and not therapeutically equivalent to Zepbound. The FDA notes specific considerations around compounded GLP-1 medications; patients should discuss these with their prescriber.

For a head-to-head cost breakdown of compounded versus brand-name options, see Compounded vs Brand GLP-1 Cost and the cheapest GLP-1 cost comparison.

Why does Zepbound cost so much?

Several factors drive Zepbound's price:

• No generic competition: tirzepatide is under patent protection; no lower-cost version is legally available from another manufacturer through standard pharmacy channels.
• High demand: GLP-1 medications for weight management have seen substantial demand growth, which affects supply chains and pricing leverage.
• U.S. drug pricing structure: the U.S. lacks centralized government price negotiation for most brand-name drugs outside of limited Medicare provisions. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) notes that prescription medications for obesity are an important and growing treatment category, but insurance coverage and affordability remain significant barriers.
• Coverage variability: inconsistent insurance coverage means many patients must pay self-pay rates even with insurance.

The self-pay vial program is Lilly's response to this affordability problem. For patients who cannot afford brand-name Zepbound even at vial rates, compounded tirzepatide from a licensed 503A pharmacy — prescribed by a U.S.-licensed physician — is the other legal path to lower-cost tirzepatide.

Is Zepbound cheaper than Mounjaro?

For cash-pay patients, yes. Mounjaro contains the same active ingredient — tirzepatide — but holds FDA approval for type 2 diabetes management rather than weight management. Mounjaro does not have an equivalent self-pay vial discount program; retail pricing runs approximately $1,000+ per month without coverage.

If you have insurance that covers Mounjaro (diabetes indication) but not Zepbound (weight management), your prescriber may be able to request a prior authorization for Zepbound coverage. This is a clinical conversation, not a guarantee. Do not switch between these medications without guidance from your prescriber.

Can I use FSA or HSA funds for Zepbound?

Possibly, with important caveats. Prescription medications for obesity treatment may be eligible for reimbursement from a flexible spending account (FSA) or health savings account (HSA) under IRC §213(d), which covers medical care expenses. Eligibility depends on your specific plan's rules, and some plan administrators require a letter of medical necessity (LMN). FSA/HSA funds are generally used for reimbursement (you pay out of pocket and submit for reimbursement) — not direct payment at the pharmacy in all cases.

Confirm eligibility and reimbursement process with your plan administrator and a qualified tax professional before relying on this. For a full breakdown of GLP-1 FSA/HSA eligibility, see Can You Use HSA/FSA for a GLP-1?

Where Nouri fits on tirzepatide cost

Nouri offers compounded tirzepatide — not Zepbound, and not FDA-approved, not the same as Zepbound or therapeutically equivalent to it — at the following prices:

• $175/month on the 6-month plan ($1,050 billed every 6 months)
• $199/month on the 3-month plan ($597 billed every 3 months)
• $225/month billed monthly

These are all-in prices: the compounded medication (when prescribed by a U.S.-licensed physician after clinical review), a personalized nutrition plan, a movement plan, and clinician support — any dose, same price. There is no separate membership fee, per-dose surcharge, or platform add-on. Medication is prepared by Jungle Jim's Pharmacy (a state-licensed 503A compounding pharmacy in Fairfield, OH) and VialsRX. Nouri is LegitScript-certified.

When comparing telehealth pricing, watch for "$99/month" or similar teaser rates that carry a separate $49–$79/month membership fee on top; compare all-in numbers. The Nouri GLP-1 telehealth pricing dataset (2026) aggregates self-pay rates across providers so you can compare directly.

Nouri is available in all 50 U.S. states. Not all applicants qualify — a U.S.-licensed physician reviews your health intake and determines whether treatment is clinically appropriate. Compounded tirzepatide is not FDA-approved and is not the same as, or therapeutically equivalent to, Zepbound or Mounjaro.

The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans.

Start your 5-minute assessment →
Questionnaire reviewed by a licensed clinician · 30-day full refund on 3-month and 6-month plans · cancel anytime · all 50 states

Related cost guides

• GLP-1 Cost 2026: Full Pricing Guide (pillar)
• Tirzepatide Cost Without Insurance
• Wegovy Cost Without Insurance
• Compounded Tirzepatide vs Zepbound: What's the Difference?
• Compounded vs Brand GLP-1 Cost
• Does Insurance Cover Wegovy & Zepbound?
• Cheapest GLP-1: Full Cost Comparison
• Can You Use HSA/FSA for a GLP-1?

Frequently asked questions

How much does Zepbound cost per month without insurance?

As of June 2026, LillyDirect self-pay Zepbound vials are approximately $299/month (2.5 mg), $399 (5 mg), and $449 (7.5–15 mg) on the Self-Pay Journey Program. The ~$1,086 retail list price applies at standard pharmacies without any discount; few self-pay patients pay it. Verify current pricing directly with LillyDirect before purchasing.

Is Zepbound cheaper than Wegovy?

At self-pay rates they are close. Zepbound vials run approximately $299–$449/month through LillyDirect; Wegovy's self-pay program (NovoCare) was approximately $349/month as of June 2026. They are different drugs — Zepbound is tirzepatide; Wegovy is semaglutide. Published trial data are studies of those specific branded molecules (SURMOUNT-1, STEP 1), not promises about any compounded product. Individual results vary.

How much are Zepbound vials through LillyDirect?

Approximately $299/month for 2.5 mg, $399 for 5 mg, and $449 for 7.5–15 mg on the Self-Pay Journey Program. To hold the $449 rate for higher doses, you must stay enrolled in the program, which generally requires refilling within approximately 45 days. Confirm current program terms at LillyDirect before enrolling.

Why is Zepbound so expensive?

There is no generic tirzepatide, demand is high, and brand-name drug prices in the U.S. reflect a market without centralized negotiation for most medications. Lilly's self-pay vials ($299–$449/month) and savings cards (as low as $25/month for covered commercial patients) exist specifically to address the affordability gap. The NIDDK and other public-health bodies have noted insurance coverage gaps as a major access barrier for obesity medications.

Does insurance cover Zepbound for weight loss?

Coverage is inconsistent. Many commercial plans exclude weight-loss medications or require prior authorization. Some PBMs have moved Zepbound on or off formulary. Check your specific plan formulary and, if denied, ask your prescriber about a prior authorization or medical exception. For more detail, see Does Insurance Cover Wegovy & Zepbound?

Is Zepbound cheaper than Mounjaro?

For cash-pay patients, yes. Zepbound has self-pay vials ($299–$449/month via LillyDirect). Mounjaro — which contains the same active ingredient, tirzepatide, but is FDA-approved for type 2 diabetes management — has no equivalent self-pay vial discount program and runs approximately $1,000+ per month at retail. Speak with your prescriber about which product and indication is appropriate for your situation.

Is there a generic version of Zepbound?

No. There is no FDA-approved generic Zepbound. Compounded tirzepatide is a separate category: it is prepared by licensed 503A compounding pharmacies and prescribed individually by licensed physicians. It is not FDA-approved and is not therapeutically equivalent to Zepbound. See the FDA's guidance on compounding for more context.

How much is Zepbound a month?

Without insurance: approximately $299–$449/month through LillyDirect self-pay vials (depending on dose). With commercial insurance that covers it, a savings card can reduce the copay to as little as $25/month. The ~$1,086 list price is the retail sticker without any program or insurance; few patients pay it. For Medicare, a Bridge program targeting ~$50/month was announced for July 2026 — verify current availability at CMS.gov.

Sources & references

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205–216. [Tier 1 — primary trial of tirzepatide molecule]
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384:989–1002. [Tier 1 — primary trial of semaglutide molecule]
3. FDA. Human Drug Compounding. U.S. Food & Drug Administration. [Tier 1 — regulatory guidance on compounding]
4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription Medications to Treat Overweight & Obesity. [Tier 1 — NIH/NIDDK obesity medication overview]
5. FDA. Postmarket Drug Safety Information for Patients and Providers — GLP-1 Agonists. [Tier 1 — FDA postmarket safety context]
6. Zepbound self-pay vials — LillyDirect (Eli Lilly). Accessed June 2026. [Tier 3 — manufacturer price source; verify before purchasing]
7. Wegovy self-pay & savings — NovoCare (Novo Nordisk). Accessed June 2026. [Tier 3 — manufacturer price comparison source]
8. CMS. Medicare GLP-1 $50 monthly access (Bridge program). CMS.gov. [Tier 1 — government program; verify current status]
9. Nouri GLP-1 Telehealth Pricing Dataset 2026. HuggingFace. [Original data — telehealth market pricing aggregation]

Medically reviewed by Amber Patel, MD · Nouri Editorial Team · Review date: June 29, 2026. Nouri content is reviewed by a U.S.-licensed clinician and updated as pricing and guidance change.

Prices and coverage described here reflect publicly available information as of June 2026 and change frequently — verify current figures with the manufacturer, your pharmacy, your insurer, and (for HSA/FSA or tax questions) a qualified tax professional before making decisions. This content is general information only; it is not medical, financial, or tax advice and does not constitute a provider-patient relationship. Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded tirzepatide is not FDA-approved and is not the same as, or therapeutically equivalent to, Zepbound® or Mounjaro®. Compounded medications are prescribed only when a U.S.-licensed physician determines treatment is clinically appropriate after reviewing a patient's health intake; not all applicants qualify. Individual results vary.